Recommend first establishing a time-bound, stoppable readiness and cross-team dependency gate for high-value customer segments, since current gaps and dependencies remain unverified, full-scale expansion carries irreversible risk, and evidence does not yet support it (F3, F4, F6, C1, C2).
Decision owner in the teaching simulationChair of the Biopharma Launch Readiness Steering Committee, in an independent instructional simulation
Human-controlled next action
The committee chair should direct an initial readiness gap assessment for high-value customer segment teams, with clearly defined stop conditions and a timeline for expansion thresholds.
What would reverse the recommendation
Reverse to full-scale expansion if validation shows high-value segment gaps are largely shared with other segments, and concrete launch-window evidence proves delaying waves would miss a critical opportunity (F1, F6, U3).
Decision review illustration
AI-generated illustration, not an actual customer scene or product screenshot. It does not demonstrate outcomes or imply endorsement.
Evidence and endorsement boundary:Independent teaching simulation. The named consulting firm supplied the public source only; it did not use, review, endorse, sponsor, certify or commission Minerva Advisor. This evidence does not claim customer results, ROI or a permanent service-level guarantee.
Inspect the evidence, then test your own decision context.
Bring a real, de-identified decision. Google sign-in and product access are required; your plan and Decision Credits apply. You remain the decision-maker, and no email or external action is sent automatically.